TapewireFind a company

person · Reporting owner

Plesha Scott M.

Disclosed activity across 2 companies

Tapewire entity
54589
SEC CIK
0001726687

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Pelthos Therapeutics Inc.PTHS · Entity 6798Director · CEO and PresidentJuly 02, 2025April 01, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Pelthos Therapeutics Inc.

Report date July 02, 2025 · Filed April 01, 2026 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect83,678 Reported balance After 2025-07-02 transaction · row 1 Amendment: may correct only part of an earlier disclosure.
1 source row

Row 1 · 2025-07-02 · Grant · Acquired 83,678 · Balance 83,678

F1: Represents shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the "Original Form 4"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I.

F2: The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the "Original Form 4"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I.

F2: The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

BIODELIVERY SCIENCES INTERNATIONAL INC

Report date March 22, 2022 · Filed March 22, 2022

Section 16 reporting ended · disclosed 2022-03-22. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2022-03-22 transaction · row 1
1 source row

Row 1 · 2022-03-22 · Other · Disposed 345,127 · Balance 0

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct0 Reported balance After 2022-03-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2022-03-22 · Disposition to issuer · Disposed 119,228 · Balance 0

F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share.

F3: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration.

Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.90Direct0 Reported balance After 2022-03-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2022-03-22 · Disposition to issuer · Disposed 245,000 · Balance 0

F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.90Direct0 Reported balance After 2022-03-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2022-03-22 · Disposition to issuer · Disposed 348,222 · Balance 0

F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.66Direct0 Reported balance After 2022-03-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2022-03-22 · Disposition to issuer · Disposed 369,721 · Balance 0

F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share.

F3: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration.

F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 02, 2025 Filed Jul 23, 2025 21:17 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 GrantStock Option · Derivative 255,000 Not disclosed Strike: $13.50 Not disclosed
Disclosure

SEC source: 0001753926-25-001175 · ownership.xml · derivative · entry 2

Plesha Scott M. · CIK 0001726687 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 255,000

Underlying: Common Stock · 255,000 shares

Expires 2035-07-02

F2 · price: On July 2, 2025, the Reporting Person was granted stock options to purchase 255,000 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years.

F2 · derivative.exercise_date: On July 2, 2025, the Reporting Person was granted stock options to purchase 255,000 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years.

Read SEC document
July 02, 2025 Filed Jul 23, 2025 21:17 UTC Pelthos Therapeutics Inc. PTHS · Entity 6798 GrantRestricted Stock Units · Derivative 83,678 Not disclosed Strike: $13.50 Not disclosed
Disclosure

SEC source: 0001753926-25-001175 · ownership.xml · derivative · entry 1

Plesha Scott M. · CIK 0001726687 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,678

Underlying: Common Stock · 83,678 shares

Expires 2035-07-02

F1 · price: On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 83,678 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years.

F1 · derivative.exercise_date: On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 83,678 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years.

Read SEC document
July 02, 2025 Filed Apr 1, 2026 17:44 UTC Amendment Pelthos Therapeutics Inc. PTHS · Entity 6798 GrantCommon Stock 83,678 $0.00 $0.00
Disclosure

SEC source: 0001919246-26-000044 · wk-form4a_1775079846.xml · nonDerivative · entry 1

Plesha Scott M. · CIK 0001726687 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,678

F1 · security: Represents shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the "Original Form 4"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I.

F2 · shares: The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F2 · price: The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

Read SEC document
March 22, 2022 Filed Mar 22, 2022 17:14 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Disposition to issuerStock Options (right to buy) · Derivative 369,721 $0.00 Strike: $3.66 $0.00
Disclosure

SEC source: 0001103021-22-000070 · wf-form4_164798368528851.xml · derivative · entry 5

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 369,721 shares

Expires not disclosed

F4 · price: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F4 · derivative.exercise_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F4 · derivative.expiration_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Read SEC document
March 22, 2022 Filed Mar 22, 2022 17:14 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Disposition to issuerStock Options (right to buy) · Derivative 348,222 $0.00 Strike: $3.90 $0.00
Disclosure

SEC source: 0001103021-22-000070 · wf-form4_164798368528851.xml · derivative · entry 4

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 348,222 shares

Expires not disclosed

F4 · price: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F4 · derivative.exercise_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F4 · derivative.expiration_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Read SEC document
March 22, 2022 Filed Mar 22, 2022 17:14 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Disposition to issuerStock Options (right to buy) · Derivative 245,000 $0.00 Strike: $3.90 $0.00
Disclosure

SEC source: 0001103021-22-000070 · wf-form4_164798368528851.xml · derivative · entry 3

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 245,000 shares

Expires not disclosed

F4 · price: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F4 · derivative.exercise_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F4 · derivative.expiration_date: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Read SEC document
March 22, 2022 Filed Mar 22, 2022 17:14 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Disposition to issuerRestricted Stock Units · Derivative 119,228 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001103021-22-000070 · wf-form4_164798368528851.xml · derivative · entry 2

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 119,228 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one Share.

F3 · price: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration.

F3 · derivative.exercise_date: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration.

F3 · derivative.expiration_date: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration.

Read SEC document
March 22, 2022 Filed Mar 22, 2022 17:14 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 OtherCommon Stock 345,127 $0.00 $0.00
Disclosure

SEC source: 0001103021-22-000070 · wf-form4_164798368528851.xml · nonDerivative · entry 1

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

Read SEC document
January 31, 2022 Filed Jan 31, 2022 17:56 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionRestricted Stock Units · Derivative 13,334 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001103021-22-000016 · wf-form4_164366973123746.xml · derivative · entry 8

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,334 shares

Expires 2022-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 31, 2019, under the Issuer's 2011 Equity Incentive Plan.

Read SEC document
January 31, 2022 Filed Jan 31, 2022 17:56 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionCommon Stock 13,334 $0.00 $0.00
Disclosure

SEC source: 0001103021-22-000016 · wf-form4_164366973123746.xml · nonDerivative · entry 3

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 345,127

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 31, 2022 Filed Jan 31, 2022 17:56 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionCommon Stock 10,869 $0.00 $0.00
Disclosure

SEC source: 0001103021-22-000016 · wf-form4_164366973123746.xml · nonDerivative · entry 2

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 331,793

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 29, 2022 Filed Jan 31, 2022 17:56 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionRestricted Stock Units · Derivative 10,869 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001103021-22-000016 · wf-form4_164366973123746.xml · derivative · entry 7

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,870

Underlying: Common Stock · 10,869 shares

Expires 2023-01-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 29, 2020, under the Plan. The remaining RSUs vest on January 29, 2023.

Read SEC document
January 27, 2022 Filed Jan 31, 2022 17:56 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionRestricted Stock Units · Derivative 21,050 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001103021-22-000016 · wf-form4_164366973123746.xml · derivative · entry 6

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,101

Underlying: Common Stock · 21,050 shares

Expires 2024-01-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 27, 2021, under the Plan. The remaining RSUs will vest in equal portions on: (i) January 27, 2023; and (ii) January 27, 2024.

Read SEC document
January 27, 2022 Filed Jan 31, 2022 17:56 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 GrantRestricted Stock Units · Derivative 66,257 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001103021-22-000016 · wf-form4_164366973123746.xml · derivative · entry 5

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,257

Underlying: Common Stock · 66,257 shares

Expires 2025-01-27

F3 · kind: The Restricted Stock Units ("RSUs") were issued to the Reporting Person on January 27, 2022, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2023; (ii) January 27, 2024; and (iii) January 27, 2025.

F4 · derivative.exercise_date: Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock.

Read SEC document
January 27, 2022 Filed Jan 31, 2022 17:56 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 GrantStock Options (right to buy) · Derivative 369,721 $3.66 Strike: $3.66 $1,353,178.86
Disclosure

SEC source: 0001103021-22-000016 · wf-form4_164366973123746.xml · derivative · entry 4

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 369,721

Underlying: Common Stock · 369,721 shares

Expires 2032-01-26

F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on January 27, 2022.

F2 · kind: The stock options were issued to the Reporting Person on January 27, 2022, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2023; (ii) January 27, 2024; and (iii) January 27, 2025.

F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on January 27, 2022, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2023; (ii) January 27, 2024; and (iii) January 27, 2025.

Read SEC document
January 27, 2022 Filed Jan 31, 2022 17:56 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionCommon Stock 21,050 $0.00 $0.00
Disclosure

SEC source: 0001103021-22-000016 · wf-form4_164366973123746.xml · nonDerivative · entry 1

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 320,924

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 12, 2021 Filed Mar 16, 2021 16:57 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionRestricted Stock Units · Derivative 20,834 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001103021-21-000033 · wf-form4_161592819765512.xml · derivative · entry 3

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,834 shares

Expires 2021-03-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 20,834 of RSUs granted to the Reporting Person on February 18, 2018 under the EIP.

Read SEC document
March 12, 2021 Filed Mar 16, 2021 16:57 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionCommon Stock 20,834 $0.00 $0.00
Disclosure

SEC source: 0001103021-21-000033 · wf-form4_161592819765512.xml · nonDerivative · entry 2

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 299,874

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 20,834 of RSUs granted to the Reporting Person on February 18, 2018 under the EIP.

Read SEC document
March 12, 2021 Filed Mar 16, 2021 16:57 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 GrantCommon Stock 20,834 $0.00 $0.00
Disclosure

SEC source: 0001103021-21-000033 · wf-form4_161592819765512.xml · nonDerivative · entry 1

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 279,040

F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 20,834 Performance Restricted Stock Units (RSUs) granted to the Reporting Person on February 18, 2018 under the Issuer's Equity Incentive Plan, as amended (the EIP) subject to certain performance measures.

Read SEC document
February 01, 2021 Filed Feb 2, 2021 18:17 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionRestricted Stock Units · Derivative 13,333 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001103021-21-000016 · wf-form4_161230683501026.xml · derivative · entry 4

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,334

Underlying: Common Stock · 13,333 shares

Expires 2022-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 31, 2019, under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs will vest on January 31, 2022.

Read SEC document
February 01, 2021 Filed Feb 2, 2021 18:17 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionCommon Stock 13,333 $0.00 $0.00
Disclosure

SEC source: 0001103021-21-000016 · wf-form4_161230683501026.xml · nonDerivative · entry 2

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 258,206

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 29, 2021 Filed Feb 2, 2021 18:17 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionRestricted Stock Units · Derivative 10,870 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001103021-21-000016 · wf-form4_161230683501026.xml · derivative · entry 3

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,739

Underlying: Common Stock · 10,870 shares

Expires 2023-01-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person on January 29, 2020, under the Issuer's 2019 Stock Option Incentive Plan. The remaining RSUs vest equally on January 29, 2022 and January 29, 2023.

Read SEC document
January 29, 2021 Filed Feb 2, 2021 18:17 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionCommon Stock 10,870 $0.00 $0.00
Disclosure

SEC source: 0001103021-21-000016 · wf-form4_161230683501026.xml · nonDerivative · entry 1

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 244,873

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 27, 2021 Filed Jan 29, 2021 19:04 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 GrantRestricted Stock Units · Derivative 63,151 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001103021-21-000004 · wf-form4_161196502447119.xml · derivative · entry 2

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,151

Underlying: Common Stock · 63,151 shares

Expires 2024-01-27

F3 · kind: The Restricted Stock Units ("RSUs") were issued to the Reporting Person on January 27, 2021, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2022; (ii) January 27, 2023; and (iii) January 27, 2024.

F4 · derivative.exercise_date: Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock.

Read SEC document
January 27, 2021 Filed Jan 29, 2021 19:04 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 GrantStock Options (right to buy) · Derivative 348,222 $0.00 Strike: $3.84 $0.00
Disclosure

SEC source: 0001103021-21-000004 · wf-form4_161196502447119.xml · derivative · entry 1

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 348,222

Underlying: Common Stock · 348,222 shares

Expires 2031-01-26

F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on January 27, 2021.

F2 · kind: The stock options were issued to the Reporting Person on January 27, 2021, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2022; (ii) January 27, 2023; and (iii) January 27, 2024.

F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on January 27, 2021, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2022; (ii) January 27, 2023; and (iii) January 27, 2024.

Read SEC document
May 18, 2020 Filed May 20, 2020 16:38 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 SaleCommon Stock 15,000 $4.52 $67,800.00
Disclosure

SEC source: 0001103021-20-000087 · wf-form4_159000710756287.xml · nonDerivative · entry 1

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 234,003

F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan.

F2 · price: On May 18, 2020, the Reporting Person sold an aggregate of 15,000 shares of the Issuer's Common Stock at a weighted average price of $4.52 per share. The highest sale price for the Common Stock was $4.58 per share and the lowest sale price was $4.46 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.

Read SEC document
March 18, 2020 Filed Mar 18, 2020 16:19 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 SaleCommon Stock 15,000 $3.55 $53,250.00
Disclosure

SEC source: 0001103021-20-000053 · wf-form4_158456275688538.xml · nonDerivative · entry 5

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 249,003

F5 · kind: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan.

F6 · price: On March 18, 2018, the Reporting Person sold an aggregate of 15,000 shares of the Issuer's Common Stock at a weighted average price of $3.55 per share. The highest sale price for the Common Stock was $3.64 per share and the lowest sale price was $3.51 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.

Read SEC document
March 16, 2020 Filed Mar 18, 2020 16:19 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionRestricted Stock Units · Derivative 20,833 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001103021-20-000053 · wf-form4_158456275688538.xml · derivative · entry 7

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,833 shares

Expires 2021-03-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 20,833 of RSUs granted to the Reporting Person on February 18, 2018 under the EIP. The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2021.

Read SEC document
March 16, 2020 Filed Mar 18, 2020 16:19 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionRestricted Stock Units · Derivative 8,334 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001103021-20-000053 · wf-form4_158456275688538.xml · derivative · entry 6

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,334 shares

Expires 2020-03-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 8,334 of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2017 under the Issuer's 2011 Equity Incentive Plan, as amended (the EIP).

Read SEC document
March 16, 2020 Filed Mar 18, 2020 16:19 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 GrantCommon Stock 20,833 $0.00 $0.00
Disclosure

SEC source: 0001103021-20-000053 · wf-form4_158456275688538.xml · nonDerivative · entry 4

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 264,003

F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 20,833 Performance RSUs granted to the Reporting Person on February 18, 2018 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures.

Read SEC document
March 16, 2020 Filed Mar 18, 2020 16:19 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionCommon Stock 20,833 $0.00 $0.00
Disclosure

SEC source: 0001103021-20-000053 · wf-form4_158456275688538.xml · nonDerivative · entry 3

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 243,170

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 20,833 of RSUs granted to the Reporting Person on February 18, 2018 under the EIP. The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2021.

Read SEC document
March 16, 2020 Filed Mar 18, 2020 16:19 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 GrantCommon Stock 8,334 $0.00 $0.00
Disclosure

SEC source: 0001103021-20-000053 · wf-form4_158456275688538.xml · nonDerivative · entry 2

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 222,337

F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 8,334 Performance RSUs granted to the Reporting Person on February 6, 2017 under the EIP, subject to certain performance measures.

Read SEC document
March 16, 2020 Filed Mar 18, 2020 16:19 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionCommon Stock 8,334 $0.00 $0.00
Disclosure

SEC source: 0001103021-20-000053 · wf-form4_158456275688538.xml · nonDerivative · entry 1

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 214,003

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 8,334 of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2017 under the Issuer's 2011 Equity Incentive Plan, as amended (the EIP).

Read SEC document
January 31, 2020 Filed Feb 4, 2020 19:29 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionRestricted Stock Units · Derivative 13,333 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001103021-20-000030 · wf-form4_158086253652230.xml · derivative · entry 2

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,667

Underlying: Common Stock · 13,333 shares

Expires 2022-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person on January 31, 2019, under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs vest equally on January 31, 2021 and January 31, 2022.

Read SEC document
January 31, 2020 Filed Feb 4, 2020 19:29 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionCommon Stock 13,333 $0.00 $0.00
Disclosure

SEC source: 0001103021-20-000030 · wf-form4_158086253652230.xml · nonDerivative · entry 1

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 205,669

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 29, 2020 Filed Jan 31, 2020 17:47 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 GrantRestricted Stock Units · Derivative 32,609 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001103021-20-000020 · wf-form4_158051082556071.xml · derivative · entry 2

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,609

Underlying: Common Stock · 32,609 shares

Expires 2023-01-29

F3 · kind: The Restricted Stock Units ("RSUs") were issued to the Reporting Person on January 29, 2020, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest in equal portions on: (i) January 29, 2021; (ii) January 29, 2022; and (iii) January 29, 2023.

F4 · derivative.exercise_date: Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock.

Read SEC document
January 29, 2020 Filed Jan 31, 2020 17:47 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 GrantStock Options (right to buy) · Derivative 158,576 $0.00 Strike: $6.17 $0.00
Disclosure

SEC source: 0001103021-20-000020 · wf-form4_158051082556071.xml · derivative · entry 1

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 158,576

Underlying: Common Stock · 158,576 shares

Expires 2030-01-29

F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is the volume-weighted average price of the Issuer's common stock for the 30-day period ending on January 28, 2020.

F2 · kind: The stock options were issued to the Reporting Person on January 29, 2020, pursuant to a grant under the Issuer's 2019 Stock Option and Incentive Plan (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) January 29, 2021; (ii) January 29, 2022; and (iii) January 29, 2023.

F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on January 29, 2020, pursuant to a grant under the Issuer's 2019 Stock Option and Incentive Plan (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) January 29, 2021; (ii) January 29, 2022; and (iii) January 29, 2023.

Read SEC document
January 21, 2020 Filed Jan 23, 2020 16:28 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 SaleCommon Stock 15,000 $5.77 $86,550.00
Disclosure

SEC source: 0001103021-20-000012 · wf-form4_157981488540534.xml · nonDerivative · entry 1

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 192,336

F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan.

F2 · price: On January 21, 2020, the Reporting Person sold an aggregate of 15,000 shares of the Issuer's Common Stock at a weighted average price of $5.77 per share. The highest sale price for the Common Stock was $5.84 per share and the lowest sale price was $5.70 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.

Read SEC document
December 11, 2019 Filed Dec 13, 2019 16:07 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 SaleCommon Stock 50,000 $6.36 $318,000.00
Disclosure

SEC source: 0001103021-19-000054 · wf-form4_157627124203029.xml · nonDerivative · entry 1

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,336

F1 · price: On December 11, 2019, the Reporting Person sold an aggregate of 50,000 shares of the Issuer's Common Stock at a weighted average price of $6.36 per share. The highest sale price for the Common Stock was $6.42 per share and the lowest sale price was $6.32 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.

Read SEC document
November 18, 2019 Filed Nov 19, 2019 16:36 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 SaleCommon Stock 25,000 $6.06 $151,500.00
Disclosure

SEC source: 0001103021-19-000037 · wf-form4_157419939601689.xml · nonDerivative · entry 1

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 257,336

F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan.

F2 · price: On November 18, 2019, the Reporting Person sold an aggregate of 25,000 shares of the Issuer's Common Stock at a weighted average price of $6.06 per share. The highest sale price for the Common Stock was $6.16 per share and the lowest sale price was $6.01 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.

Read SEC document
March 20, 2019 Filed Mar 22, 2019 18:02 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 GrantRestricted Stock Units · Derivative 20,833 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000899243-19-008815 · doc4.xml · derivative · entry 8

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,667

Underlying: Common Stock · 20,833 shares

Expires 2021-03-19

F4 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 20,833 Performance RSUs granted to the Reporting Person on February 18, 2018 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures.

F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 20,833 Performance RSUs granted to the Reporting Person on February 18, 2018 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures.

F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 20,833 Performance RSUs granted to the Reporting Person on February 18, 2018 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures.

Read SEC document
March 20, 2019 Filed Mar 22, 2019 18:02 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionRestricted Stock Units · Derivative 20,833 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000899243-19-008815 · doc4.xml · derivative · entry 7

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,667

Underlying: Common Stock · 20,833 shares

Expires 2021-03-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 20,833 of RSUs granted to the Reporting Person on February 18, 2018 under the EIP. The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2020 and March 2021.

F3 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 20,833 of RSUs granted to the Reporting Person on February 18, 2018 under the EIP. The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2020 and March 2021.

F3 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 20,833 of RSUs granted to the Reporting Person on February 18, 2018 under the EIP. The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2020 and March 2021.

Read SEC document
March 20, 2019 Filed Mar 22, 2019 18:02 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 GrantRestricted Stock Units · Derivative 8,333 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000899243-19-008815 · doc4.xml · derivative · entry 6

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,334

Underlying: Common Stock · 8,333 shares

Expires 2020-03-19

F2 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 8,333 Performance RSUs granted to the Reporting Person on February 6, 2017 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures.

F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 8,333 Performance RSUs granted to the Reporting Person on February 6, 2017 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures.

F2 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 8,333 Performance RSUs granted to the Reporting Person on February 6, 2017 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures.

Read SEC document
March 20, 2019 Filed Mar 22, 2019 18:02 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionRestricted Stock Units · Derivative 8,333 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000899243-19-008815 · doc4.xml · derivative · entry 5

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,334

Underlying: Common Stock · 8,333 shares

Expires 2020-03-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 8,333 of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2017 under the Issuer's 2011 Equity Incentive Plan, as amended (the EIP). The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2020.

F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 8,333 of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2017 under the Issuer's 2011 Equity Incentive Plan, as amended (the EIP). The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2020.

F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 8,333 of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2017 under the Issuer's 2011 Equity Incentive Plan, as amended (the EIP). The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2020.

Read SEC document
March 20, 2019 Filed Mar 22, 2019 18:02 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 GrantCommon Stock 20,833 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-008815 · doc4.xml · nonDerivative · entry 4

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 282,833

F4 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 20,833 Performance RSUs granted to the Reporting Person on February 18, 2018 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures.

F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 20,833 Performance RSUs granted to the Reporting Person on February 18, 2018 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures.

Read SEC document
March 20, 2019 Filed Mar 22, 2019 18:02 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionCommon Stock 20,833 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-008815 · doc4.xml · nonDerivative · entry 3

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 261,503

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 20,833 of RSUs granted to the Reporting Person on February 18, 2018 under the EIP. The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2020 and March 2021.

F3 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 20,833 of RSUs granted to the Reporting Person on February 18, 2018 under the EIP. The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2020 and March 2021.

Read SEC document
March 20, 2019 Filed Mar 22, 2019 18:02 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 GrantCommon Stock 8,333 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-008815 · doc4.xml · nonDerivative · entry 2

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,670

F2 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 8,333 Performance RSUs granted to the Reporting Person on February 6, 2017 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures.

F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 8,333 Performance RSUs granted to the Reporting Person on February 6, 2017 under the EIP, subject to certain performance measures. The remainder of the PRSUs under this grant will vest after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures.

Read SEC document
March 20, 2019 Filed Mar 22, 2019 18:02 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionCommon Stock 8,333 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-008815 · doc4.xml · nonDerivative · entry 1

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,337

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 8,333 of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2017 under the Issuer's 2011 Equity Incentive Plan, as amended (the EIP). The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2020.

F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 8,333 of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2017 under the Issuer's 2011 Equity Incentive Plan, as amended (the EIP). The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2020.

Read SEC document
March 01, 2019 Filed Mar 1, 2019 18:46 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionRestricted Stock Units · Derivative 11,666 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000899243-19-005536 · doc4.xml · derivative · entry 2

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,666 shares

Expires 2019-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 11,666 of Restricted Stock Units granted to the Reporting Person on February 29, 2016 under the Issuer's 2011 Equity Incentive Plan, as amended.

F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 11,666 of Restricted Stock Units granted to the Reporting Person on February 29, 2016 under the Issuer's 2011 Equity Incentive Plan, as amended.

F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 11,666 of Restricted Stock Units granted to the Reporting Person on February 29, 2016 under the Issuer's 2011 Equity Incentive Plan, as amended.

Read SEC document
March 01, 2019 Filed Mar 1, 2019 18:46 UTC BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 Exercise / conversionCommon Stock 11,666 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-005536 · doc4.xml · nonDerivative · entry 1

Plesha Scott M. · CIK 0001726687 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 224,004

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 11,666 of Restricted Stock Units granted to the Reporting Person on February 29, 2016 under the Issuer's 2011 Equity Incentive Plan, as amended.

F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 11,666 of Restricted Stock Units granted to the Reporting Person on February 29, 2016 under the Issuer's 2011 Equity Incentive Plan, as amended.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.